AB
TSHA icon

Amalgamated Bank’s Taysha Gene Therapies TSHA Stock Holding History

Amalgamated Bank’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,939
Closed -$38K – 2735
2025
Q4 		$38K Buy
6,939
+1,405
+25% +$6.82K ﹤0.01% 1901
2025
Q3 		$18K Hold
5,534
– – ﹤0.01% 2181
2025
Q2 		$13K Hold
5,534
– – ﹤0.01% 2333
2025
Q1 		$8K Hold
5,534
– – ﹤0.01% 2495
2024
Q4 		$10K Hold
5,534
– – ﹤0.01% 2450
2024
Q3 		$11K Hold
5,534
– – ﹤0.01% 2420
2024
Q2 		$12K Buy
+5,534
New +$16.1K ﹤0.01% 2367
2022
Q2 		– Sell
-3,535
Closed -$23K – 3201
2022
Q1 		$23K Buy
+3,535
New +$26.4K ﹤0.01% 2763

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Amalgamated Bank's TSHA Position: Q1 2026 in Review

Amalgamated Bank sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 6,939 shares — an estimated $38K sold.

Amalgamated Bank first reported a position in TSHA in Q1 2022 and held it in 8 quarters. The position peaked at $38K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Amalgamated Bank reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 6,939 Taysha Gene Therapies shares in Q1 2026, an estimated $38K.
  • Amalgamated Bank first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 8 quarters.
  • Amalgamated Bank's Taysha Gene Therapies position peaked at $38K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.